Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc

BACKGROUND: Temsavir (TMR), the active agent of the gp120-directed attachment inhibitor fostemsavir (FTR), the CD4-directed attachment inhibitor ibalizumab (IBA), and the CCR5 antagonist maraviroc (MVC) are antiretroviral agents that target steps in HIV-1 viral entry. Although mechanisms of inhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Ronald, Gartland, Margaret, Li, Zhufang, Zhou, Nannan, Cockett, Mark, Beloor, Jagadish, Lataillade, Max, Ackerman, Peter, Krystal, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Basic Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654283/
https://www.ncbi.nlm.nih.gov/pubmed/34628442
http://dx.doi.org/10.1097/QAD.0000000000003097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654283/
https://www.ncbi.nlm.nih.gov/pubmed/34628442
http://dx.doi.org/10.1097/QAD.0000000000003097

Ejemplares similares